Quince Therapeutics announces special shareholder meeting
QNCX•Special shareholder meeting planned for September 2026
Quince Therapeutics will hold a virtual special shareholder meeting in September 2026.
Votes will be sought to allow conversion of Series C Non-Voting Convertible Preferred Stock into common stock. Ballots will also cover issuance of common stock tied to warrant exercises and assumed Orphai options.
Shareholders will vote on increasing authorized common shares to 275,000,000 from 250,000,000. Other items include adopting a 2026 Equity Incentive Plan, a 2026 ESPP, and a potential meeting adjournment.
